Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) EPS (Basic): 2017-2025

Historic EPS (Basic) for Protagonist Therapeutics (PTGX) over the last 8 years, with Sep 2025 value amounting to -$0.62.

  • Protagonist Therapeutics' EPS (Basic) fell 14.81% to -$0.62 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.77, marking a year-over-year decrease of 73.36%. This contributed to the annual value of $4.47 for FY2024, which is 421.58% up from last year.
  • Protagonist Therapeutics' EPS (Basic) amounted to -$0.62 in Q3 2025, which was down 12.73% from -$0.55 recorded in Q2 2025.
  • Protagonist Therapeutics' EPS (Basic)'s 5-year high stood at $3.41 during Q1 2024, with a 5-year trough of -$0.84 in Q2 2022.
  • Moreover, its 3-year median value for EPS (Basic) was -$0.54 (2024), whereas its average is $0.16.
  • Per our database at Business Quant, Protagonist Therapeutics' EPS (Basic) tumbled by 233.33% in 2021 and then skyrocketed by 608.96% in 2024.
  • Quarterly analysis of 5 years shows Protagonist Therapeutics' EPS (Basic) stood at -$0.77 in 2021, then climbed by 9.09% to -$0.70 in 2022, then skyrocketed by 174.29% to $0.52 in 2023, then surged by 309.62% to $2.13 in 2024, then declined by 14.81% to -$0.62 in 2025.
  • Its EPS (Basic) stands at -$0.62 for Q3 2025, versus -$0.55 for Q2 2025 and -$0.19 for Q1 2025.